Molecular tongs containing amino acid mimetic fragments: New inhibitors of wild-type and mutated HIV-1 protease dimerization

Journal of Medicinal Chemistry

Volumn 49, Issue 15, 2006, Pages 4657-4664

  Bannwarth, Ludovic ^b   Kessler, Albane ^a   Pèthe, St́phanie ^a   Collinet, Bruno ^b   Merabet, Naïma ^a   Boggetto, Nicole ^b   Sicsic, Sames ^a   Reboud Ravaux, Michèle ^b   Ongeri, Sandrine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT JACQUES MONOD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; AMPRENAVIR; INDINAVIR; NAPHTHALENE DERIVATIVE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; DIMERIZATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; IN VITRO STUDY; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN DEGRADATION; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION; WILD TYPE;

EID: 33746701342     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060576k     Document Type: Article

References (39)

1. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease Is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
2. Peng, C.; Ho, B. K.; Chang, T. W.; Chang, N. T. Role of Human Immunodeficiency Virus Type l-Specific Protease in Core Protein Maturation and Viral Infectivity. J. Virol. 1989, 63, 2550-2556.
3. Tomasselli, A. G.; Heinrickson, R. L. Targeting the HIV-Protease in AIDS Therapy: A Current Clinical Perspective. Biochim. Biophys. Acta 2000, 1477, 189-214.
4. De Clercq, E. New Anti-HIV Agents and Targets. Med. Res. Rev. 2002, 22, 531-565.
5. Golsmith, D. R.; Perry, C. M. Atazanavir. Drugs 2003, 63, 1679-1693.
6. Gulick, R M. New Antiretroviral Drugs. Clin. Microbiol. Infect. 2003, 186-193.
7. D'Aquila, R. T.; Schapiro, J. M.; Brun-Vezinet, F.; Clotet, B.; Conway, B.; Demeter, L. M.; Grant, R. M.; Johnson, V. A.; Kuritzkes, D. R.; Loveday, C.; Shafer, R. W.; Richman, D. D. Drug Resistance Mutations in HIV-1. Top. HIV Med. 2002, 10, 21-25.
8. Larder, B. Mechanisms of HIV-1 Drug Resistance. AIDS 2001, 15 (Suppl. 5), S27-S34.
9. Ishima, R.; Ghirlando, R.; Tozser, J.; Gronenborn, A. M.; Torchia, D. A.; Louis, J. M. Folded Monomer of HIV-1 Protease. J. Biol. Chem. 2001, 276, 49110-49116.
10. Todd, M. J.; Semo, M.; Freire, E. The Structural Stability of HIV-1 Protease. J. Mol. Biol. 1998, 283, 475-488.
11. Schinazi, R. F.; Larder, B. A.; Mellors, J. W. Mutations in Retroviral Genes Associated with Drug-Resistance. Antiviral News 1997, 5, 129-142.
12. Kuiken, C. L.; Foley, B.; Hahn, B.; Korber, B.; Marx, P. A.; McCutchan, F.; Mellors, J. W.; Wolinksy, S. Technical Report LA-UR02-2877; Los Alamos National Laboratory: Los Alamos, NM, 2001.
13. Gustchina, A.; Weber, I. T. Comparative Analysis of the Sequences and Structures of HIV-1 and HIV-2 Proteases. Proteins 1991, 10, 325-329.
14. Boggetto, N.; Reboud-Ravaux, M. Dimerization Inhibitors of HIV-1 Protease. Biol. Chem. 2002, 383, 1321-1324.
15. Schramm, H. J.; Nakashima, H.; Schramm, W.; Wakayama, H.; Yamamoto, N. HIV-1 Reproduction Is Inhibited by Peptides Derived from the N- and C-Termini of HIV-1 Protease. Biochem. Biophys. Res. Commun. 1991, 179, 847-851.
16. Zhang, Z.-Y.; Poorman, R. A.; Maggiora, L. L.; Heinrickson, R. L.; Kedzy, F. J. Dissociative Inhibition of Dimeric Enzymes. Kinetic Characterization of the Inhibition of HIV-1 Protease by Its COOH-Terminal Tetrapeptide. J. Biol. Chem. 1991, 266, 15591-15594.
17. Franciskovich, J.; Houseman, K.; Mueller, R.; Chmielewski, J. A Systematic Evaluation of the Inhibition of HIV-1 Protease by Its C- and N-Terminal Peptides. Bioorg. Med. Chem. Lett. 1993, 3, 765-768.
18. Schramm, H. J.; de Rosny, E.; Reboud-Ravaux, M.; Büttner, J.; Dick, A.; Schramm, W. Lipopeptides as Dimerization Inhibitors of HIV-1 Protease. Biol. Chem. 1999, 380, 593-596.
19. Dumond, J.; Boggetto, N.; Schramm, H. J.; Schramm, W.; Takahashi, M.; Reboud-Ravaux, M. Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of immunodeficiency virus-1 protease. Biochem. Pharmacol. 2002, 7550, 1-6.
20. Zutshi, R.; Franciskovich, J.; Slultz, M.; Schweitzer, B.; Bishop, P.; Wilson, M.; Chmielewski, J. Targeting the Dimerization Interface of HIV-1 Protease: Inhibition with Cross-Linked Interfacial Peptides. J. Am. Chem. Soc. 1997, 119, 4841-4845.
21. Ulysse, L. G.; Chmielewski, J. Restricting the Flexibility of Crosslinked, Interfacial Peptide Inhibitors of HIV-1 Protease. Bioorg. Med. Chem. Lett. 1998, 8, 3281-3286.
22. Bouras, A.; Boggetto, N.; Benatalah, Z.; de Rosny, E.; Sicsic, S.; Reboux-Ravaud, M. Design, Synthesis, and Evaluation of Conformationally Constrained Tongs, New Inhibitors of HIV-1 Protease Dimerization. J. Med. Chem. 1999, 42, 957-962.
23. Merabet, N.; Dumond, J.; Collinet, B.; Van Baelinghem, L.; Boggetto, N.; Ongeri, S.; Ressad, F.; Reboud-Ravaux M.; Sicsic, S. New Constrained "Molecular Tongs" Designed To Dissociate HIV-1 Protease Dimer. J. Med. Chem. 2004, 47, 6392-6400.
24. Breccia, P.; Boggetto, N.; Pérez-Fernández, R.; Van Gool, M.; Takahashi, M.; René, L.; Prados, P.; Badet, B.; Reboud-Ravaux, M.; de Mendoza, J. Dimerization Inhibitors of HIV-1 Protease Based on a Bicyclic Guanidinium Subunit. J. Med. Chem. 2003, 46, 5196-5207.
25. (a) Nowick, J. S.; Holmes, D. L.; Mackin, G.; Noronha, G.; Shaka, A. J.; Smith, E. M. An Artificial β-Sheet Comprising a Molecular Scaffold, a β-Strand Mimic, and a Peptide Strand. J. Am. Chem. Soc. 1996, 118, 2764-2765.
26. (b) Nowick, J. S.; Pairish, M.; Lee, I. Q.; Holmes, D. L.; Ziller, J. W. An Extended β-Strand Mimic for a Larger Artificial β-Sheet J. Am. Chem. Soc. 1997, 119, 5413-5424.
27. (c) Nowick, J. S.; Chung, D. M.; Maitra, K.; Stigers, K. D.; Sun, Y. An Unnatural Amino Acid That Mimics a Tripeptide β-Strand and Forms β-Sheetlike Hydrogen-Bonded Dimers. J. Am. Chem. Soc. 2000, 122, 7654-7661.
28. Nowick, J. S.; Cary, J. M.; Tsai, J. H. A Triply Templated Artificial β-Sheet J. Am. Chem. Soc. 2001, 123, 5176-5180.
29. (e) Tsai, J. H.; Nowick, J. S. Two New β-Strand Mimics Bioorg. Med. Chem. 1999, 7, 29-38.
30. (f) Nowick J. S.; Smith, E. M.; Ziller, J. W.; Shaka, A. J. Three-Stranded Mixed Artificial β-Sheets. Tetrahedron 2002, 58, 727-739.
31. Sanderson, P. E. J.; Lyle, T. A.; Cutrona, K. J.; Dyer, D. L.; Dorsey, B. D.; McDonough, C. M.; Naylor-Olsen, A. M.; Chen, I.-W.; Chen, Z.; Cook, J. J.; Cooper, C. M.; Gardell, S. J.; Hare, T. R.; Krueger, J. A.; Lewis, S. D.; Lin, J. H.; Lucas, B. J., Jr.; Lyle, E. A.; Lynch, J. J., Jr.; Stranieri, M. T.; Vastag, K.; Yan, Y.; Shafer, J. A.; Vacca, J. P. Efficacious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates. J. Med. Chem. 1998, 41, 4466-4474.
32. Clemente, J. C.; Hemrajani, R.; Blum, L. E.; Goodenow, M. M.; Dunn, B. M. Secondary Mutations M361 and A71V in the Human Immuodeficiency Virus Type 1 Protease Can Provide an Advantage for the Emergence of the Primary Mutation D30N. Biochemistry 2003, 15029-15035.
33. Ahlsen, G.; Hulten, J.; Poliakov, A.; Lindgren, M. T.; Alterman, M.; Samuelsson, B.; Hallberg, A.; Danielson, U. H. Resistance Profile of Cyclic and Linear Inhibitors of HIV-1 Protease. Antiviral Chem. Chemother. 2002, 13, 27-37.
34. Pazhanisamy, S.; Stuver, C. M.; Cullinan, A. B.; Margolin, N.; Rao, B. G.; Livingston, D. Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-Resistant Variants. J. Biol. Chem. 1996, 17979-17985.
35. Maschera, B.; Darby, G.; Palu, G.; Wright, L. L.; Tisdale, M.; Myers, R.; Blair, E. D.; Furfine, E. S. Mutations in the Viral Protease That Confer Resistance to Saquinavir Increase the Dissociation Rate Constant of the Protease-Saquinavir Complex. J. Biol. Chem. 1996, 271, 33231-33235.
36. Ohtaka, H.; Schön, A.; Freire, E. Multidrug Resistance to HIV-1 Protease Inhibition Requires Cooperative Coupling between Distal Mutations. Biochemistry 2003, 42, 13659-13666.
37. Muzammil, S.; Ross, P.; Freire, E. A Major Role for a Set of Non-Active Site Mutations in the Development of HIV-1 Protease Drug Resistance. Biochemistry 2003, 42, 631-638.
38. Shulz, M. D.; Ham, Y.-U.; Lee, S.-G.; Davis, D. A.; Brown, C.; Chmielewski, J. Small-Molecule Dimerization Inhibitors of Wild-Type and Mutant HIV Protease: A Focused Library Approach. J. Am. Chem. Soc. 2004, 126, 9886-9887.
39. Billich, A.; Hammerschmid, F.; Winkler, G. Purification Assay and Kinetic Features of HIV-1 Proteinase. Biol. Chem. Hoppe-Seyler 1990, 371, 265-272.